(CercleFinance.com) – The group announces five-year data on KEYTRUDA® (pembrolizumab) combined with chemotherapy. These data showed a durable survival benefit compared to chemotherapy alone in two studies of metastatic non-small cell lung cancer (NSCLC).
The five-year overall survival rate is 19.4% and 18.4% for KEYTRUDA plus chemotherapy in the KEYNOTE-189 and KEYNOTE-407 studies, respectively.
In first-line metastatic non-small cell lung cancer, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials.
‘The overall survival results obtained in the KEYNOTE-189 and KEYNOTE-407 studies changed the way patients with metastatic non-small cell lung cancer were treated and made the combination of KEYTRUDA and chemotherapy a treatment first-line treatment for this devastating disease,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.
‘Today, with more than five years of follow-up, these studies continue to show impressive results in terms of survival and durable responses for patients receiving KEYTRUDA in combination with chemotherapy. In fact, in both studies, of the approximately 55 patients who completed two years of treatment, around 70% were still alive at five years.’
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about MERCK AND CO INC in real time: